Real-world ticagrelor for preventing stroke
Part of Brain & nervous system, Heart & circulation clinical trials.
This study is looking at how well the blood thinner ticagrelor works to prevent new strokes and what side effects it may cause in real-life settings. If you are already taking ticagrelor for stroke, joining this study may help researchers learn more about its benefits and risks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a diagnosis of ischemic cerebrovascular disease (stroke or mini-stroke caused by a blocked blood vessel in the brain).
- You must be taking ticagrelor (a blood thinner) to prevent or treat the effects of your stroke.
- You must be willing to provide written consent to participate.
- You must not have signs of bleeding in the brain (from a CT or MRI scan).
- You must not have other serious conditions like cancer or an allergy to ticagrelor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether low-dose colchicine added to ticagrelor (a blood-thinning medicine) helps prevent another ischemic stroke in people whose first stroke was caused by clogged arteries. It aims to lower the risk of repeat stroke after recovery from a recent event.
This study tests whether the drug cilostazol, when added to your usual aspirin or clopidogrel, can help prevent another stroke. It is being done in Africa and may be a good option if you've recently had a stroke or mini-stroke and want to lower your risk of another one.
This trial tests whether switching to a simpler antiplatelet medication (ticagrelor) after a mild stroke or high-risk TIA can prevent another stroke while reducing the risk of bleeding. It is for people who have not received clot-busting treatment or had a large stroke.
This trial tests whether adding aspirin to either ticagrelor or clopidogrel (two antiplatelet medicines) can help prevent another stroke in people who recently had a minor stroke or TIA affecting a large brain artery. It is for people who started antiplatelet treatment within 24 hours of their symptoms.
This trial tests whether adding ticagrelor or cilostazol to aspirin is better than aspirin alone for preventing another stroke. It is for patients who recently had a minor stroke or a transient ischemic attack (TIA) caused by a blockage in a large artery.
This trial tests whether the drug ticagrelor, which helps prevent blood clots, can reduce the risk of a stroke occurring days after a mild form of bleeding in the brain. It is given as an add-on to the standard treatment for the bleeding aneurysm.
Hear when a new Cerebral Infarction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.